An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)

NKGen Biotech, Inc.

Summary

Open-Label Extension Protocol to SNK01-AD01 Study

Description

Open-label extension study to assess long-term safety and tolerability of SNK01 administered as an intravenous (IV) infusion every 3 weeks in participants with Alzheimer's Disease

Eligibility

Age range: 40–85 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: Participants will be considered eligible for participation in the study if all the following criteria are satisfied: * The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the subject). * Participants must…

Interventions

Biological
SNK01
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

Location

Behavioral Research Specialists, LLC
Glendale, California
harry@brstrials.com (888) 255-5798

An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)

Summary

Description

Eligibility

Interventions

Location

Run this study?

Details

Conditions